Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 6

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 6
---
 |     |            |      |     |                |      |     |            |      |     |                |      |     |            |      |     |            |       |     |            |      |
| $                        |                                            6.16 |     | $              | 5.44 |     | $          | 3.45 |     | $              | 4.37 |     | $          | 4.52 |     | $              | 2.68 |     | $          | 6.21 |     | $          | -0.47 |     | $          | 9.36 |

Our sponsor and members of our management team will directly or indirectly own our securities following this offering, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. Further, each of our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination. Additionally, each of our officers and directors presently has, and any of them in the future may have additional, fiduciary, contractual or other obligations or duties to one or more other entities pursuant to which such officer or director is or will be required to present a business combination opportunity to such entities. See“ Proposed Business— Sourcing of Potential Business Combination Targets” and“ Management— Conflicts of Interest” for additional information. Prior to this offering, there has been no public market for our units, ordinary shares or rights. We intend to apply to list our units on The Nasdaq Global Market (“Nasdaq”) under the symbol “DMAAU” on or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq. The ordinary shares and rights constituting the units will begin separate trading on the 52 ndday following the date of this prospectus (or, if such date is not a business day, the following business day) unless Clear Street LLC, the representative of the underwriters in this offering, informs us of its decision to allow earlier separate trading, subject to our filing a Current Report on Form 8 -Kwith the Securities and Exchange Commission (the “SEC”) containing an audited balance sheet of the company reflecting our receipt of the gross proceeds of this offering and issuing a press release announcing